Stockreport

Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes [Yahoo! Finance]

Incannex Healthcare Inc.  (IXHL) 
PDF Incannex Healthcare Enhanced Phase 2 dose-optimization study designed to accelerate development and support a streamlined Phase 3 program MELBOURNE, Australia and N [Read more]